An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Research payments
$166,287,839
Through program year 2025, $166,287,839 in research payments was reported against An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis, across 973 payments, paid by Novartis Pharmaceuticals Corporation.
- Paid by
- Novartis Pharmaceuticals Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $29,071,259 | 188 |
| 2024 | Research | $33,510,505 | 153 |
| 2023 | Research | $29,153,002 | 245 |
| 2022 | Research | $32,994,282 | 97 |
| 2021 | Research | $23,807,142 | 96 |
| 2020 | Research | $15,547,623 | 96 |
| 2019 | Research | $2,204,024 | 98 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Miguel Paz Soldan Salt Lake City, UT Named on 11 payments
- Enrique Alvarez Aurora, CO Named on 9 payments
- Bhupesh Dihenia Lubbock, TX Named on 9 payments
- Carrie Hersh Las Vegas, NV Named on 8 payments
- Khurram Bashir Birmingham, AL Named on 8 payments
- Mirela Cerghet Detroit, MI Named on 8 payments
- Bharathy Sundaram Sherman, TX Named on 8 payments
- Donald Negroski Sarasota, FL Named on 8 payments
- Wm Honeycutt Maitland, FL Named on 7 payments
- Sara Qureshi Billings, MT Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.